Agenus Inc. — Q2 2022 Form 10-Q Summary
Business context and reporting period
Agenus is a clinical-stage immuno-oncology company developing antibody therapies, cell therapies and vaccine adjuvants. This unaudited Form 10-Q covers the quarter and six months ended June 30, 2022. The company has no products approved for commercial sale and has incurred losses since inception.
Financial results and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Total revenue | $20.9 million | $10.7 million | $46.9 million | $22.4 million |
| Operating loss | $44.6 million | $66.4 million | $80.0 million | $107.8 million |
| Net loss attributable to Agenus common stockholders | $46.5 million | $83.3 million | $94.9 million | $137.1 million |
| Loss per share, basic and diluted | $0.17 | $0.37 | $0.35 | $0.65 |
| Research and development expense | $45.0 million | $45.5 million | $87.4 million | $82.2 million |
| General and administrative expense | $18.9 million | $16.7 million | $37.9 million | $33.0 million |
- Cash, cash equivalents and short-term investments totaled $238.3 million at June 30, 2022, down $68.6 million from year-end 2021. Cash and cash equivalents on the balance sheet were $228.4 million.
- Net cash used in operations was $95.8 million for the first half, compared with $98.3 million in the prior-year period. Investing activities used $11.6 million, including $23.0 million of property and equipment purchases and $10.0 million of asset-sale proceeds. Financing provided $43.8 million, including $47.4 million net proceeds from at-the-market equity sales.
- Current assets were $288.9 million and current liabilities $159.7 million. Stockholders’ equity was $13.6 million.
- Outstanding debt principal was approximately $13.8 million; the $13.0 million 2015 subordinated notes bear 8% interest and mature in February 2023. Separately, the net liability for sold future royalties and milestones was $264.5 million.
- Management stated that June 30 resources were expected to fund liquidity needs for more than one year from issuance of the statements. It also cited spending adjustments and potential partnerships, milestones, asset sales, project financing and equity issuance as funding options.
Material changes and unusual items
- Revenue increased year over year, but the increase included $17.3 million of Q2 royalty sales milestone revenue after GSK vaccine sales crossed the final HCR agreement threshold. The milestone is paid through royalties as earned; Agenus recorded a receivable and recognizes revenue as the underlying royalties are earned.
- First-half research and development revenue included a $5.0 million Gilead milestone. First-half non-cash royalty revenue was $17.8 million, versus $16.3 million a year earlier.
- Operating loss narrowed, while net loss also improved. Q2 non-operating income included a $6.6 million gain on sale of property and equipment and a $2.8 million gain on partial liability forgiveness. These gains are unusual and are not recurring operating revenue.
- First-half R&D expense rose 6%, mainly from personnel and subsidiary activity; G&A expense rose 15%, primarily from subsidiary activity. The company said it reduced expenses by approximately 20% in May 2022 to improve efficiency and focus on leading programs.
- Agenus raised $47.4 million net through ATM share sales in the first half, issuing approximately 22.8 million shares. Common shares issued rose from 256.9 million at December 31, 2021 to approximately 282.9 million at June 30, 2022. On August 5, authorized common shares increased from 400 million to 800 million.
Outlook, risks and contingencies
- Management expected worldwide botensilimab studies in microsatellite-stable colorectal cancer, melanoma and pancreatic cancer to begin in the second half of 2022. The filing gives no specific financial guidance.
- Management expects significant future losses and additional capital needs. It cannot reliably estimate the cost or timing of completing development programs or when material cash inflows may begin.
- Key risks include clinical efficacy and safety uncertainty, trial enrollment and timing, regulatory approval, manufacturing scale-up and supply, competition, reliance on collaborators, and the possibility that additional financing may be unavailable or dilutive. Interim clinical data may change as trials mature.
- The company withdrew its balstilimab monotherapy cervical-cancer BLA after FDA advice following a competitor’s full approval, and said it was no longer pursuing U.S. registration of balstilimab plus zalifrelimab for second-line cervical cancer.
- Agenus filed suit against Recepta in January 2022 alleging breach of their collaboration agreement concerning development plans and marketing rights in South America. The outcome was described as too early to predict. The filing reports no other material legal proceedings.
- Foreign exchange exposure is primarily in the euro, Swiss franc and British pound; the company reported no material change in its market-risk approach and does not use derivatives or hedging for these exposures.
Important facts for investors to verify
- Whether the expected second-half 2022 botensilimab trials began as planned, and the status and maturity of clinical data.
- How much of reported revenue and future cash receipts depends on HCR royalties and milestones, Gilead milestones, and other partners.
- Cash burn, capital expenditure needs and runway assumptions, particularly given the February 2023 maturity of the subordinated notes.
- Further ATM equity issuance, dilution, and the effect of the increase in authorized shares.
- Developments in the Recepta litigation and in the company’s partnerships, including any milestone, option or termination decisions.